Who is at risk
- Age — most often diagnosed between 65 and 74; it is rare under 45.
- MGUS (monoclonal gammopathy of undetermined significance) — a symptomless blood finding that precedes essentially all myeloma, carrying roughly a 1% per year chance of progressing. If you have been told you have MGUS, that is worth monitoring, not panicking about.
- Smouldering myeloma — a further step along, with more abnormal cells but still no organ damage.
- Race — myeloma is about twice as common in Black Americans, who also develop it younger. This disparity is real and under-recognised.
- Sex — slightly more common in men.
- Family history of myeloma or MGUS, and obesity.
- Some chemical and radiation exposures, including certain occupational and environmental exposures.
Finding it early
There is no population screening for myeloma, and its early symptoms are the vaguest in oncology — which is why it is so often diagnosed late, after months of being treated for something else.
Clinicians remember the features as CRAB: Calcium raised, Renal (kidney) impairment, Anaemia, Bone lesions. In everyday language that is: persistent bone pain (classically the back or ribs), a bone that breaks with little force, unexplained tiredness from anaemia, kidney function that has quietly worsened, frequent infections, thirst and confusion from high calcium.
Back pain in an older adult that is worse at night, does not improve with rest, or comes with unexplained anaemia or kidney changes deserves a myeloma screen — simple blood and urine tests for abnormal proteins (serum protein electrophoresis and free light chains). It is an inexpensive test that is not ordered often enough.
People with known MGUS or smouldering myeloma are monitored with regular blood tests — that surveillance is the closest thing to early detection this disease has.
How it’s diagnosed
Diagnosis combines blood and urine tests for the abnormal (monoclonal) protein and free light chains, a bone marrow biopsy to measure the percentage of plasma cells, and whole-body imaging — low-dose CT, MRI or PET/CT — to look for bone lesions. Plain X-ray skeletal surveys are outdated.
Genetic testing of the marrow (FISH) is essential, not optional. Findings such as t(4;14), t(14;16) and del(17p) define high-risk disease and change treatment intensity. Ask whether yours has been done.
The distinction that matters most: MGUS and smouldering myeloma need monitoring, not treatment. Active myeloma — defined by organ damage or specific high-risk biomarkers — needs treatment.
Staging explained simply
Myeloma does not use the TNM system, and the usual local/regional/distant framework does not describe it meaningfully — because myeloma arises in bone marrow, which is everywhere. (SEER classifies 96% of cases as "distant" for that reason alone, which tells you almost nothing clinically.)
Instead myeloma uses the Revised International Staging System (R-ISS), built from blood tests and genetics rather than anatomy:
- Stage I — low beta-2 microglobulin, normal albumin, normal LDH, and no high-risk genetic changes.
- Stage II — neither stage I nor stage III.
- Stage III — high beta-2 microglobulin plus either high-risk genetics or raised LDH.
So when someone with myeloma says "stage III," they mean something quite different from a person with colon cancer. It reflects biology, not spread.
Grading and biology
There is no 1–3 grade in myeloma. Its equivalent is cytogenetic risk — the genetic changes inside the plasma cells.
Standard-risk disease (hyperdiploidy, t(11;14)) generally responds well and durably. High-risk disease (del(17p), t(4;14), t(14;16), 1q gain, or more than one such change) tends to relapse sooner and is usually treated more intensively from the start.
The other measurement that increasingly guides care is minimal residual disease (MRD) — testing the marrow for one myeloma cell among a million normal ones. Reaching MRD-negative status is associated with longer remission.
How it’s treated
Modern induction uses three or four drugs together — typically a proteasome inhibitor, an immunomodulatory drug, an anti-CD38 antibody and a steroid. These combinations are the main reason survival has doubled.
Autologous stem cell transplant — high-dose therapy using your own stem cells to rescue the marrow — remains standard for eligible patients and deepens remission. Eligibility depends on fitness more than birthday.
Maintenance therapy afterwards, usually lenalidomide, extends remission for years.
Radiation is genuinely useful in myeloma, and specifically so. Myeloma is very radiosensitive, and modest doses relieve bone pain quickly, treat a plasmacytoma (a single collection of myeloma cells), prevent or treat fracture in a weakened bone, and treat spinal cord compression — which is an emergency. Radiation does not cure myeloma, but for a person in bone pain it can restore function within weeks.
Supportive care is not optional here: bone-strengthening drugs (bisphosphonates or denosumab), infection prevention and vaccination, kidney protection, and thrombosis prophylaxis with immunomodulatory drugs.
CAR T-cell therapy and bispecific antibodies now produce deep responses in relapsed disease.
Where CureRays fits: palliative and functional radiation for bone disease, plasmacytoma and cord compression is squarely our work — and it is often the intervention that most immediately changes how a person feels.
What the guidelines say
In broad strokes: distinguish MGUS and smouldering myeloma (monitor) from active myeloma (treat); do genetic risk testing at diagnosis; treat with three- or four-drug induction; consider autologous stem cell transplant in eligible patients; continue maintenance; give bone-protective therapy and infection prophylaxis to everyone; use radiation for painful bone lesions, plasmacytoma, impending fracture and cord compression; and use newer immune therapies at relapse.
Your team will follow national guidelines such as those from the National Comprehensive Cancer Network (NCCN). The above is a plain-language overview of the general approach, not the guideline itself. NCCN publishes free NCCN Guidelines for Patients®.
Outcomes and odds of cure
Five-year relative survival for myeloma is approximately 64% (NCI SEER, SEER 21 excluding IL, 2015–2021). In 2025 an estimated 36,110 people will be diagnosed and about 12,030 will die of it. Source: SEER Cancer Stat Facts: Myeloma.
We are deliberately not showing a stage table. SEER classifies 96% of myeloma as "distant" simply because bone marrow is throughout the body, so that breakdown would mislead rather than inform. Ask your team for figures based on your R-ISS stage and cytogenetic risk, which are what actually predict your course.
The trend is the real story: five-year survival was about 30% in the mid-1990s and is roughly 64% now, and death rates have been falling about 2.6% a year (SEER, 2014–2023). Because these figures describe people diagnosed years ago, they understate what current four-drug regimens achieve.
On the word "curable": myeloma is generally considered treatable but not curable, and it is fair to want that said plainly. Many people now live a decade or more with good quality of life, moving through successive remissions. A minority achieve very long, deep remissions that look much like cure.
These are population statistics from the National Cancer Institute's SEER program. They describe large groups of people, not any one person, and lag current treatment by several years. They cannot predict what will happen to you.
Side effects and how we watch for them
Steroids (dexamethasone) cause sleeplessness, mood swings, raised blood sugar and stomach irritation — often the most disruptive part of treatment, and frequently the part people are least warned about. Dose can be adjusted; say something.
Bortezomib can cause peripheral neuropathy — report tingling or numbness early, because dose or schedule changes can prevent it becoming permanent.
Immunomodulatory drugs raise clot risk, so you will be given blood-thinning prophylaxis. Anti-CD38 antibodies raise infection risk.
Bone drugs carry a small risk of osteonecrosis of the jaw — have dental work done before starting where possible.
Radiation effects depend on the site; bone pain often improves within one to two weeks.
How it is assessed: graded at each visit on a standard scale, with blood counts, kidney function, calcium and the myeloma protein tracked continuously — the protein level is how response is measured.
Follow-up, remission and survivorship
Remission in myeloma is measured chemically — by how far the abnormal protein falls. Complete response means it is undetectable; MRD-negative means no myeloma cell found among a million marrow cells. Monitoring continues indefinitely, because relapse is expected at some point and is treatable when caught on blood tests before it causes organ damage.
Follow-up is blood and urine protein tests every few weeks to months, kidney function, calcium, and imaging when new pain appears. New or changing bone pain should be reported rather than waited out, and new leg weakness, numbness or bladder problems require same-day assessment for spinal cord compression.
Survivorship focuses on bone health, infection prevention and vaccination, kidney protection (avoid unnecessary anti-inflammatories and contrast where possible), fatigue, and the psychological weight of living with a relapsing condition. That last one is real and treatable.
Questions people actually ask
I have MGUS. Am I going to get myeloma?
Most people with MGUS never develop myeloma. The risk is roughly 1% per year, which is why it is monitored with periodic blood tests rather than treated. Monitoring is the appropriate response, not treatment and not alarm.
Is myeloma curable?
Generally it is considered treatable but not curable, and we would rather say that plainly than imply otherwise. Many people now live a decade or more through successive remissions, and a minority achieve very long deep remissions that resemble cure.
Why radiation if it can't cure it?
Because it works quickly on the problems that hurt most — bone pain, a weakened bone at risk of breaking, a solitary plasmacytoma, or pressure on the spinal cord. Relieving those changes daily life even when the disease itself continues.
Why does my back hurt so much?
Myeloma weakens bone by disrupting normal bone turnover, causing lesions and compression fractures in the spine and ribs. Bone-strengthening drugs, radiation and sometimes vertebral procedures all help. Pain should be treated, not endured.
Am I too old for a stem cell transplant?
Eligibility depends on fitness, organ function and other conditions far more than on age alone. Plenty of people in their seventies are transplanted. It is a conversation worth having rather than assuming the answer.
Informational only, not medical advice — confirm with your care team.
Go deeper on myeloma
Read the full plain-language guide, or talk with us about radiation for bone pain or plasmacytoma.